About: Biomarkers of Infection: Are They Useful in the ICU?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Biomarkers of Infection: Are They Useful in the ICU? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Biomarkers of Infection: Are They Useful in the ICU?
Creator	Schuetz, Philipp Gregoriano, Claudia Heilmann, Eva
source	PMC
abstract	Biomarkers are increasingly used in patients with serious infections in the critical care setting to complement clinical judgment and interpretation of other diagnostic and prognostic tests. The main purposes of such blood markers are (1) to improve infection diagnosis (i.e., differentiation between bacterial vs. viral vs. fungal vs. noninfectious), (2) to help in the early risk stratification and thus provide prognostic information regarding the risk for mortality and other adverse outcomes, and (3) to optimize antibiotic tailoring to individual needs of patients (“antibiotic stewardship”). Especially in critically ill patients, in whom sepsis is a major cause of morbidity and mortality, rapid diagnosis is desirable to start timely and specific treatment. Besides some biomarkers, such as procalcitonin, which is well established and has shown positive effects in regard to utilization of antimicrobials and clinical outcomes, there is a growing number of novel markers from different pathophysiological pathways, where the final proof of an added value to clinical judgment and ultimately clinical benefit to patients is still lacking. Without a doubt, the addition of blood biomarkers to clinical medicine has had a strong impact on the way we care for patients today. Recent trials show that as an adjunct to other clinical and laboratory parameters these markers provide important information about risks for bacterial infection and resolution of infection. Moreover, biomarkers can help to optimize management of patients with serious illness in the intensive care unit, thereby offering more individualized treatment courses with overall improvements in clinical outcomes.
has issue date	2019-10-04(xsd:dateTime)
bibo:doi	10.1055/s-0039-1696689
bibo:pmid	31585473
has license	no-cc
sha1sum (hex)	2607fce24937addc60c906cead98bec5a9b044f1
schema:url	https://doi.org/10.1055/s-0039-1696689
resource representing a document's title	Biomarkers of Infection: Are They Useful in the ICU?
has PubMed Central identifier	PMC7117078
has PubMed identifier	31585473
schema:publication	Semin Respir Crit Care Med
resource representing a document's body	covid:2607fce24937addc60c906cead98bec5a9b044f1#body_text
is schema:about of	named entity '95% CI' named entity 'positive and negative predictive values' named entity 'biomarkers' named entity 'tumor necrosis factor' named entity 'antibiotics' named entity 'patient outcomes' named entity 'infection' named entity '95% confidence interval' named entity 'immune cells' named entity 'transcriptional' named entity 'Procalcitonin' named entity 'self-limited' named entity 'sepsis' named entity 'pathophysiological' named entity 'metabolism' named entity 'Clostridium difficile infections' named entity 'work-up' named entity 'patient care' named entity 'sepsis' named entity 'noninfectious' named entity 'infection' named entity 'antibiotics' named entity 'China' named entity 'health care' named entity 'cytokines' named entity 'sepsis' named entity 'FDA' named entity 'biomarker' named entity 'viral infections' named entity 'mortality rates' named entity 'receiver operating characteristic' named entity 'cytokine' named entity 'transcriptional' named entity 'targeted therapy' named entity 'diagnostic method' named entity 'antibiotic stewardship' named entity 'therapeutic benefit' named entity 'work-up' named entity 'infection' named entity 'Surviving Sepsis Campaign' named entity 'ICU' named entity 'patient care' named entity 'biomarkers' named entity 'renal impairment' named entity 'infection' named entity 'bacterial infection' named entity 'proteomics' named entity 'white blood cells' named entity 'respiratory infections' named entity 'interferon-gamma' named entity 'antibiotic' named entity 'antibiotic treatment' named entity 'lactate' named entity 'sepsis' named entity 'ligands' named entity 'antibiotic' named entity 'immunosuppressed' named entity 'pathogen' named entity 'sepsis' named entity 'antibiotics' named entity 'antibiotic' named entity 'gene expression' named entity 'antibiotic therapy' named entity 'gene expression profiling' named entity 'retrospective study' named entity 'Antibiotic overuse' named entity 'intensive care unit' named entity 'noninfectious' named entity 'IL-6' named entity 'sepsis' named entity 'signs and symptoms' named entity 'morbidity' named entity 'antibiotics' named entity 'cardiovascular' named entity 'noninfectious' named entity 'randomized controlled trials' named entity 'long time' named entity 'mmol/L' named entity 'risk stratification'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software